NZYM - 500 Beiträge pro Seite

[teicker]

Hot Bio-tech company Synthetech (NASDAQ: NZYM)

We believe that NZYM is in play as a potential take over target -- more to come in the following days -- please STAY TUNED.

[teicker]

IGYM****IGYM****IGYM****IGYM****IGYM****IGYM****IGYM****IGYM

REMINDER - Market Watch News Flash - New Internet Issue

Significant short term trading profits still available in a new Internet issue (Ticker Symbol: IGYM)

Integrity Messenger Corporation (Ticker Symbol: IGYM, http://finance.yahoo.com/q?s=IGYM.pk) began trading when the market opened on Tuesday, January 20th -- and although it ran through our near term target of $1.92 as stated in our previous email, it has not yet hit our longer term target of $3.68. If you missed out on the short term target, DO NOT MISS OUT on the longer term target! If you have been sitting on the sidelines waiting and watching others collect huge gains on our News Flashes, WAIT NO MORE. Buy IGYM NOW!

Remember, Integrity Messenger (http://www.integritymessenger.com) is a cross-compatible, co-branded instant messaging solution that works with all of the major messaging services -- AOL Instant Messenger, MSN Messenger, ICQ, and Yahoo Messenger. In plain English, Integrity Messenger allows you to instant message someone from your AOL IM to their MSN IM; it makes all instant messaging platforms compatible. This technology, as you know, is white-hot and this stock will continue to grow!

Again, our IGYM targets:
Short Term Target: $1.92
Longer Term Target: $3.68

Not too long ago, only a handful of people were using instant messaging programs -- but now that the value of direct, instant communication has been realized, IM has become the latest luxury turned into necessity.

Instant messaging use in the United States alone is expected to grow at an average of 110% annualized over the next 5 years. As a result of this extreme usage growth, analysts predict Integrity Messenger will have strong revenues in 2004. If Integrity Messenger just stays in accordance with what the analysts feel are conservative revenue and growth estimates, IGYM will be an unbelievable growth story.

IGYM is a micro cap stock, thus, it is appropriate for investors who set aside a portion of their portfolio for extreme growth in high risk equities. IGYM is an exciting company with a very exciting technology -- go get it now, good luck and God Bless!!!


IGYM****IGYM****IGYM****IGYM****IGYM****IGYM****IGYM****IGYM

Hot Bio-tech company Synthetech (NASDAQ: NZYM)

We believe that NZYM is in play as a potential take over target -- more to come in the following days -- please STAY TUNED.

IGYM****IGYM****IGYM****IGYM****IGYM****IGYM****IGYM****IGYM

Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, goals, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements."

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as: "projects", "foresee", "expects", "estimates," "believes," "understands" "will", "anticipates," or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks,securities must be understood as information provided and not investment advice. Emerging Equity Alert advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice.

In compliance with Section 17(b), we disclose the holding of independently purchased shares of IGYM prior to the publication of this report. Be aware of an inherent conflict of interest resulting from such holdings due to our intent to profit from the liquidation of these shares. Shares may be sold at any time, even after positive statements have been made regarding the above company.

[teicker]

Press Release Source: Synthetech, Inc.


Synthetech Reports Third Quarter Fiscal 2004 Results
Tuesday January 27, 7:42 pm ET


ALBANY, Ore., Jan. 27 /PRNewswire-FirstCall/ -- Synthetech, Inc. (Nasdaq: NZYM - News) today announced financial results for the third quarter and first nine months of fiscal 2004, which ended December 31, 2003. Revenue for the third quarter of fiscal 2004 was $2.9 million, a 27% decrease compared to revenue of $4.0 million in the third quarter of fiscal 2003. Operating loss for the current quarter was $354,000, compared to operating income of $1.3 million for the same period last year. Net loss for the quarter was $350,000, or $0.02 per share, compared to net income of $838,000, or $0.06 per share, for last year`s corresponding period.
For the first nine months of fiscal 2004, revenue of $6.5 million resulted in both an operating and net loss of $2.7 million, or $0.19 per share. For the comparable period last year, revenues of $8.9 million resulted in operating loss of $116,000 and a net loss of $46,000, or $0.00 per share. International sales, mainly to Western Europe, were $1.4 million for the first nine months of fiscal 2004 and 2003.

Synthetech, Inc.
Condensed Statements of Operations

Three Months Ended Nine Months Ended
(in thousands, except December 31, December 31,
per share data) 2003 2002 2003 2002
(unaudited)
Revenue $2,914 $3,991 $6,530 $8,867
Cost of revenue 2,612 2,001 7,309 6,995
Gross income (loss) 302 1,990 (779) 1,872

Research and development 167 207 539 524
Selling, general and
administrative 489 444 1,373 1,464
Total operating
expense 656 651 1,912 1,988

Operating income (loss) (354) 1,339 (2,691) (116)

Interest income 6 15 26 49
Interest expense (2) (3) (6) (7)
Income (loss) before
income taxes (350) 1,351 (2,671) (74)

Provision (benefit) for
income taxes -- 513 -- (28)
Net income (loss) $(350) $838 $(2,671) $(46)

Basic and diluted income
(loss) per share $(0.02) $0.06 $(0.19) $(0.00)



Commenting on the financial results, M. "Sreeni" Sreenivasan, President and CEO, said, "Our third quarter revenue exceeded revenue for each of the first and second quarters of fiscal 2004 and we expect that our fourth quarter revenue will exceed third quarter revenue. Additionally, cash flow from operations for the third quarter of fiscal 2004 was slightly positive and we ended the quarter with a cash balance of $3.9 million. Revenue volatility is inherent in supplying Peptide Building Blocks (PBBs) to the pharmaceutical development market and is largely affected by the timing and size of large-scale projects. Due to the slower than expected ramp-up of a major customer`s newly marketed drug, the customer has reduced the aggregate size of a large-scale order from approximately $4.4 million to approximately $2.2 million, including the cancellation of a $600,000 delivery scheduled for the fourth quarter of fiscal 2004. The customer also has pushed back the scheduled delivery dates for the remaining $2.2 million of the order to the second half of fiscal 2005. As a result, our large-scale order commitments for fiscal 2005 currently stand at approximately $3.9 million. The mix of drug development projects using our PBBs in various phases of the clinical pipeline continues at an active pace."

Commenting on recent efforts to expand marketing activities, Mr. Sreenivasan added, "We are pleased to welcome Dr. Claude Colin to our team as our first European Director of Business development. Based in Belgium, Dr. Colin will work on expanding our ongoing presence in the European market. Dr. Colin joins Synthetech with over 20 years of executive level experience with European fine chemical and pharmaceutical firms. We expect Dr. Colin`s efforts will complement those of Dr. Joseph Murphy, our Director of Business Development based in New Jersey, by positioning our senior business development staff in close proximity to the heavy concentration of pharmaceutical accounts in the US and Western Europe."

Management continues to believe that the Company is well positioned to take advantage of business opportunities as a supplier of PBBs for pharmaceutical and other projects. Synthetech operates in a challenging business environment, characterized by the unpredictable dynamics and life cycle of pharmaceutical projects, which can lead to rapid fluctuations in the mix of projects and revenues from period to period. Because the uncertainties inherent in development projects remain outside the Company`s control, it remains difficult to predict the progress, timing and revenue potential of these projects.

About Synthetech

Synthetech`s PBBs are used predominantly by pharmaceutical companies and others to make a wide range of peptide, peptidomimetic small molecule and other drugs under development or on the market for the treatment of AIDS, cancer, cardiovascular and other diseases. The Company has established a worldwide reputation in a unique product and technology niche as a leading supplier to the pharmaceutical and life sciences industry.